Tadenan

07/01/2008 - "Efficacy of tadenan was studied in combined treatment of 30 patients suffering from chronic prostatitis complicated by sterility. "
07/01/2008 - "[Efficacy of tadenan in chronic prostatitis complicated by sterility]."
09/01/1991 - "This clinical study has been designed to evaluate the efficacy of an extract of Pygeum Africanum (Tadenan) (Roussel-Pharma) in patients suffering from prostatic hypertrophy or chronic prostatitis. "

01/01/1977 - "20 patients with benign prostatic hypertrophy were admitted to a double-blind noncrossover study for evaluation of the effect of Tadenan. "
01/01/1977 - "A clinical and urodynamic study of tadenan in the treatment of benign prostatic hypertrophy."
05/01/2012 - "Pygeum africanum (Tadenan) is a popular phytotherapeutic agent used in the treatment of symptomatic benign prostatic hyperplasia. "
03/01/2009 - "Tadenan, a drug of plant origin, was given to 27 patients with documented prostatic adenoma for 3-12 months. "
03/01/2009 - "[Tadenan treatment of prostatic adenoma]."

05/01/2002 - "However, treating obstructed rabbits with 30 mg./kg. Tadenan daily resulted in reduced bladder hypertrophy, improved compliance, improved contractile responses to nearly normal levels of isolated bladder strips to all stimuli tested and reversal of obstruction induced structural damage to cellular and subcellular organelle membranes. "
06/01/2000 - "The alteration in the expression of myosin isoforms associated with obstruction-induced hypertrophy is reversed close to normal in the detrusor smooth muscle from Tadenan-treated obstructed rabbits."

07/01/2008 - "Efficacy of tadenan was studied in combined treatment of 30 patients suffering from chronic prostatitis complicated by sterility. "
07/01/2008 - "[Efficacy of tadenan in chronic prostatitis complicated by sterility]."

01/01/2005 - "The results of the current study show that Tadenan pretreatment at the clinically relevant dose of 3.0 mg/kg body wt./day protected the bladder from the contractile dysfunctions induced by bilateral ischemia followed by reperfusion. "
01/01/2005 - "The current study was designed to determine whether pre-treating rabbits with a clinically relevant dose of Tadenan could prevent the bladder from developing the contractile dysfunctions that are induced by bilateral ischemia followed by reperfusion. "
01/01/1999 - "The current study was designed to determine if Tadenan pretreatment of rabbits protected the bladder against the development of contractile dysfunctions induced by unilateral ischemia and to correlate effects in the presence and absence of Tadenan with the molecular response in relation to two of the most prominent genes activated by both ischemia and partial outlet obstruction: Hsp-70 and c-myc. "
01/01/2005 - "Low-dose tadenan protects the rabbit bladder from bilateral ischemia/ reperfusion-induced contractile dysfunction."
01/01/1999 - "Tadenan pretreatment protected the nonischemic side of the bladder from the development of contractile dysfunctions, and unilateral ischemia resulted in a 10-fold increase in the expression of both Hsp-70 and c-myc in the bladders isolated from the Tadenan-treated rabbits. "